| Inhibitor |
Cell type |
Consequences |
Reference |
| AR-A014418 |
Panc-1 |
Decreased proliferation and tumor growth, gemcitabine sensitization |
39 |
| AR-A014418 |
Panc-1, MiaPaCa-2, BxPC-3 |
Decreased proliferation, gemcitabine sensitization (in vitro & in vivo),
radiosensitization, decreased migration & invasion |
36 |
| siGSK3β & AR-A014418 |
MiaPaCa-2, Panc-1 |
Decreased NFκB activity, caspase-3 cleavage, decreased proliferation |
40 |
| AR-A014418 |
BxPC-3, Panc-1, HPAC, PK-1, PK-8 |
Decreased proliferation, no gemcitabine sensitization (except Panc-1) |
43 |
| AR-A014418 |
Panc-1, BxPC-3 |
Increased TRAIL-induced apoptosis (in vitro & in vivo) |
38 |
| AR-A014418, shGSK3β, SB216763 |
MiaPaCa-2, BxPC-3 |
Decreased proliferation, increased apoptosis |
26 |
| shGSK3β, LiCl |
BxPC-3 & Panc-1 |
Resistance to radiation (in vitro & in vivo) |
37 |
| siGSK3β |
Panc-1 |
Resistance to radiation, increased HGF, c-Met activation |
[Figure 4] |
|
